Androgen receptor footprint on the way to prostate cancer progression

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 279-285

  Hodgson, Myles C ^a   Bowden, Wayne A ^a   Agoulnik, Irina U ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Androgen receptor; Castration resistance; Metastasis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST;

ANIMAL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; HUMAN; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84861610571     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0743-7     Document Type: Article

References (46)

1. Johnson TE (2006) Recent results: biomarkers of aging. Exp Gerontol 41(12): 1243-1246.
2. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1): 11-22.
3. Agoulnik IU, Weigel NL (2006) Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99(2): 362-372.
4. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C et al (2010) Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 105(4): 462-467.
5. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G (2004) High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surgical Pathol 28(7): 928-934.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1): 33-39.
7. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP (2001) Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 98(19): 10823-10828.
8. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W et al (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474(7351): 390-394.
9. Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS (2011) High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 58(5): 766-772.
10. Linja MJ, Visakorpi T (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92(4): 255-264.
11. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102(4): 1151-1156.
12. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate [Epub ahead of print].
13. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107(39): 16759-16765.
14. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6): 2305-2313.
15. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikstrom P (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4): e19059.
16. Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001.
17. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2): 245-256.
18. Lonard DM, Lanz RB, O'Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28(5): 575-587.
19. Agoulnik IU, Weigel NL (2009) Coactivator selective regulation of androgen receptor activity. Steroids 74(8): 669-674.
20. Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM et al (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65(17): 7959-7967.
21. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, 3rd, Erdem H, Frolov A, Smith CL et al (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66(21): 10594-10602.
22. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY et al (2005) SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65(17): 7976-7983.
23. Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY et al (2008) Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68(13): 5460-5468.
24. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4): 256-269.
25. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191(3): 239-244.
26. Culig Z (2011) Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2): 308-314.
27. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC (2009) Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8(3): 665-671.
28. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K et al (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68(16): 6762-6769.
29. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q et al (2010) Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 70(8): 3309-3319.
30. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE (2007) Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 38(11): 1611-1620.
31. Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z et al (2008) Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med 12(6B): 2790-2798.
32. Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M et al (2011) Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol 178(1): 79-87.
33. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D (2008) Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 68(19): 8173-8182.
34. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10(3): 233-239.
35. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F et al (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69(7): 2912-2918.
36. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G et al (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71(4): 1325-1333.
37. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17(5): 443-454.
38. van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA (2007) The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 67(13): 1432-1438.
39. Pontes J Jr, Srougi M, Borra PM, Dall' Oglio MF, Ribeiro-Filho LA, Leite KR (2010) E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 18(2): 179-184.
40. Medici D, Hay ED, Olsen BR (2008) Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 19(11): 4875-4887.
41. Kim K, Lu Z, Hay ED (2002) Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 26(5): 463-476.
42. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferriere JM (2010) The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 28(5): 473-479.
43. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC (2005) Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 23(6): 402-406.
44. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL et al (2011) Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71(2): 572-582.
45. Memarzadeh S, Cai H, Janzen DM, Xin L, Lukacs R, Riedinger M, Zong Y, Degendt K et al (2011) Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci USA 108(19): 7962-7967.
46. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON (2006) Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 103(20): 7789-7794.